AstraZeneca PLC (LON:AZN) reached a new 52-week high on Friday . The stock traded as high as GBX 8,982 ($117.35) and last traded at GBX 8,913 ($116.45), with a volume of 590796 shares. The stock had previously closed at GBX 8,668 ($113.25).
AZN has been the subject of a number of research reports. Berenberg Bank lowered their price target on shares of AstraZeneca from £100 ($130.65) to GBX 9,500 ($124.12) and set a “buy” rating for the company in a report on Wednesday, September 1st. Citigroup reiterated a “buy” rating and issued a £105 ($137.18) price target on shares of AstraZeneca in a research note on Monday, September 20th. Credit Suisse Group set a GBX 9,000 ($117.59) price objective on shares of AstraZeneca in a research note on Monday, September 20th. Liberum Capital reissued a “buy” rating and issued a GBX 9,220 ($120.46) price objective on shares of AstraZeneca in a report on Monday, June 7th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a £102 ($133.26) price target on shares of AstraZeneca in a report on Wednesday, September 1st. Two equities research analysts have rated the stock with a sell rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Buy” and a consensus price target of GBX 9,501.54 ($124.14).
The stock has a market cap of £137.02 billion and a PE ratio of 42.32. The company has a quick ratio of 1.01, a current ratio of 1.23 and a debt-to-equity ratio of 190.47. The firm has a 50 day moving average price of GBX 8,413.98 and a 200 day moving average price of GBX 8,040.03.
About AstraZeneca (LON:AZN)
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
Featured Article: Most Volatile Stocks
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.